Lv2
108 积分 2023-09-17 加入
Pathologic response to hypofractionation in locally advanced cervical cancer
17天前
已完结
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy
18天前
已完结
Pathologic response to hypofractionation in locally advanced cervical cancer
18天前
已完结
Single-port robotic surgery in gynecologic oncology: feasibility and safety after 1 year of implementation
18天前
已完结
Minimally Invasive Surgery, Intraoperative Capsule Rupture, and Survival in Early Ovarian Cancer
18天前
已完结
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial
7个月前
已完结
Is PORTEC-4a the tipping point in endometrial cancer management?
7个月前
已完结
Chemoradiotherapy With or Without Simultaneous Integrated Boost for Cervical Cancer With Full-Thickness Stromal Invasion
10个月前
已完结
Which is the best timing to assess response after chemoradiation in locally advanced cervical cancer (BRILACC)?
10个月前
已完结
Application of Neoadjuvant Docetaxel Plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial
1年前
已完结
皖公网安备34019202002308
